Sugi Predict

Sugi Predict / Compounds / SCHEMBL1268366

SCHEMBL1268366

SCHEMBL1268366

CC(C)(C)OC(=O)Nc1nc(Cl)c(C=O)s1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LCK P06239 8/20 0.46
▸ MEN1 O00255 5/20 0.45
▸ MAPT P10636 5/20 0.45
▸ KMT2A Q03164 5/20 0.45
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ LMNA P02545 3/20 0.43
▸ PSMD14 O00487 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ GLA P06280 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ ATR Q13535 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ PI4KB Q9UBF8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5402789 0.84 LCK (0.52) LCKCA1CA2PI4KB
SCHEMBL20421990 0.83 CA1 (0.44) LCKCA1CA2PI4KB
SCHEMBL367235 0.83 CA1 (0.47) LCKCA1CA2PI4KB
SCHEMBL27459069 0.81 CA1 (0.42) LCKCA1CA2PI4KB
SCHEMBL31214147 0.81 CA1 (0.42) LCKCA1CA2ATRPI4KB
SCHEMBL20877490 0.79 LCK (0.48) LCKCA1CA2ATRPI4KB
SCHEMBL20422013 0.79 MAPT (0.51) MEN1MAPTKMT2ALMNAPSMD14
SCHEMBL25403792 0.78 LCK (0.53) LCKCA1CA2ATRPI4KB
SCHEMBL16753973 0.78 LCK (0.53) LCKCA1CA2LMNAATR
SCHEMBL25261549 0.78 LCK (0.53) LCKCA1CA2ATRPI4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138991-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS INC (US) 2026-05-21 — — US disclosed
EP-4705298-A2 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES Moma Therapeutics, Inc. (US) 2026-03-11 — — EP disclosed
US-12559508-B2 Semi-saturated bicyclic derivatives and related uses MOMA THERAPEUTICS, INC. (US) 2026-02-24 — — US disclosed
EP-4611895-A1 NOVEL COMPOUNDS FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHIES AC Immune SA (CH) 2025-09-10 — — EP disclosed
US-20250230171-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2025-07-17 — — US disclosed
US-12180221-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-12-31 — — US disclosed
WO-2024211836-A2 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. (US) 2024-10-10 — — WO disclosed
EP-4419551-A1 O-GLCNACASE (OGA) INHIBITOR COMBINATION THERAPY Eli Lilly and Company (US) 2024-08-28 — — EP disclosed
CN-112469476-B 5-Methyl-4-fluoro-thiazol-2-yl compounds 伊莱利利公司 2024-07-16 — — CN disclosed
US-11999726-B2 5-methyl-4-fluoro-thiazol-2-yl compounds ELI LILLY AND COMPANY 2024-06-04 — — US disclosed
US-7569688-B2 Propane-1, 3-dione derivative ASTELLAS PHARMA INC. (JP) 2009-08-04 — — US disclosed
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC 2009-03-19 — — US disclosed
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC 2009-03-19 — — US disclosed
WO-2008064265-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 — — WO disclosed
WO-2008064265-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 — — WO disclosed
WO-2008063888-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 — — WO disclosed
WO-2008063888-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 — — WO disclosed
WO-2008064255-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 — — WO disclosed
CN-1186326-C Propane-1, 3-dione derivatives YAMANOUCHI PHARMA CO LTD (JP) 2005-01-26 — — CN disclosed
CN-1440391-A Propane-1, 3-dione derivatives YAMANOUCHI PHARMA CO LTD (JP) 2003-09-03 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor KIT, FLT3, FLT1 LCK 120/4885MEN1 1083/4885MAPT 4266/4885
US-20250230171-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES POLQ, POLB, POLK LCK 2470/4885MEN1 4398/4885MAPT 3527/4885
US-20260138991-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES POLA1, SUB1, CTDSP1 LCK 4319/4885MEN1 3429/4885MAPT 2143/4885
US-12559508-B2 Semi-saturated bicyclic derivatives and related uses POLA1, CTDSP1, SUB1 LCK 4514/4885MEN1 3507/4885MAPT 2256/4885
US-12180221-B2 Compounds and uses thereof NLN, ACHE, CLN6 LCK 3250/4885MEN1 1807/4885MAPT 22/4885
US-11999726-B2 5-methyl-4-fluoro-thiazol-2-yl compounds MAPT, PSEN2, PSEN1 LCK 1111/4885MEN1 1104/4885MAPT 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.